RAPP Rapport Therapeutics, Inc.

Nasdaq www.rapportrx.com


$ 26.15 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 15:59:59 EDT
QQQ $ 611.34 $ 0.00 (0 %)
DIA $ 466.73 $ 1.78 (0.38 %)
SPY $ 671.85 $ 3.53 (0.53 %)
TLT $ 91.42 $ 0.00 (0 %)
GLD $ 378.74 $ -2.69 (-0.71 %)
$ 24.9
$ 25.18
$ 24.40 x 100
$ 27.00 x 2
$ 24.85 - $ 26.17
$ 6.43 - $ 42.27
304,249
na
908.8M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces ...

Core News & Articles

Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company d...

 rapport-reports-promising-epilepsy-study-outcomes-plans-phase-3-trials-next-year

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety pr...

Core News & Articles

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price ta...

Core News & Articles

RAPP: 176% | Rapport Therapeutics' Phase 2a Trial Of RAP-219 In Drug-Resistant Focal Onset Seizures Met Its Primary Endpoin...

Core News & Articles

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients a...

Core News & Articles

Rapport Therapeutics, Inc.

Core News & Articles

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of ...

Core News & Articles

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION